A naukri.com initiative
Brighter Side of News
1d
244
Image Credit: Brighter Side of News
First head-to-head trial compares tirzepatide and semaglutide – Results are in!
- A recent clinical trial compared the effectiveness of tirzepatide and semaglutide in treating obesity in individuals without diabetes.
- Participants taking tirzepatide lost more weight (20.2% of body weight) compared to those on semaglutide (13.7% of body weight).
- Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide only targets GLP-1.
- The trial, funded by Eli Lilly, involved 751 adults and showed significant weight loss with tirzepatide.
- More participants on tirzepatide achieved major weight loss milestones compared to those on semaglutide.
- Both drugs were associated with gastrointestinal side effects like nausea and abdominal pain.
- Women tended to have slightly better results with both medications, and overall, tirzepatide showed higher weight reductions.
- Tirzepatide's dual-action mechanism is believed to contribute to its superior efficacy over semaglutide.
- Future research is focusing on developing even more potent treatments for obesity, such as the triple G compound retatrutide.
- The study highlighted the clinical benefits of significant weight loss, improving health markers like blood pressure and blood sugar.
Read Full Article
14 Likes
For uninterrupted reading, download the app